What was the primary driver of the significant increase in net income in the second quarter of 2018?

The significant increase in net income to $555 million ($0.40 EPS) in Q2 2018, compared to $146 million ($0.11 EPS) in Q2 2017, was primarily driven by a substantial tax benefit of $250 million resulting from the settlement of transfer pricing disputes with the IRS and the impacts of the Tax Cuts and Jobs Act (TCJA). This, combined with increased net sales, contributed to the improved profitability.

How are the recent acquisitions performing and contributing to the company's results?

The company completed several acquisitions in early 2018, including Cryterion Medical, NxThera, and nVision Medical. While specific revenue contributions for these acquisitions in Q2 are not broken out separately in the provided text, the company notes that these acquisitions are being integrated into their respective business units (e.g., NxThera into Urology and Pelvic Health, contributing to BPH business growth). The company views these as strategic additions to its portfolio.

What is the company's outlook on debt and liquidity?

Boston Scientific maintained a solid liquidity position with $208 million in cash and cash equivalents and had access to a $2.25 billion revolving credit facility. Total debt stood at $6.49 billion as of June 30, 2018. The company was in compliance with its debt covenants, specifically its leverage ratio, and expressed confidence that its current resources and cash flow generation would be sufficient to fund operations, investments, and debt service for the next twelve months.

What were the main reasons for the slight decrease in gross profit margin?

The gross profit margin decreased slightly to 70.3% in Q2 2018 from 72.0% in Q2 2017. The primary reason cited was the negative impact of foreign currency fluctuations. This decrease was partially offset by positive contributions from manufacturing cost reductions achieved through process improvement and restructuring programs.

BSX 10-Q Quarterly Report Q2 FY2018 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported strong financial results for the second quarter and the first half of 2018, driven by robust net sales growth across its key segments, particularly in Rhythm and Neuro and Cardiovascular. Net sales increased by 10.3% to $2.49 billion in Q2 2018 and by 10.2% to $4.87 billion for the first six months, with operational growth highlighting the underlying business strength. The company's strategic acquisitions, including Cryterion Medical, NxThera, and nVision Medical, are beginning to contribute to revenue and are being integrated into relevant business units. Despite increased operating expenses, particularly in R&D, and some foreign currency headwinds, the company demonstrated improved profitability year-over-year, partly due to the resolution of significant tax matters. BSX also managed its debt effectively, maintaining compliance with financial covenants. Overall, the filing indicates a company experiencing solid top-line growth fueled by both organic expansion and strategic M&A. Investors should note the company's continued investment in R&D to maintain its innovation pipeline and the ongoing impact of various legal and restructuring matters, which are being managed. The company's balance sheet remains solid, supported by a strong credit facility and debt management strategies.

Financial Highlights

49 data points

Beta

Revenue

$2.49B

0.7% Gross Margin

Net Income

$555.00M

0.2% Net Margin

EPS (Diluted)

$0.40

Total Assets

$19.61B

Cash & Equivalents

$208.00M

Free Cash Flow

-$477.00M

Financial Statements

Beta

Revenue	$2.49B
Cost of Revenue	$739.00M
Gross Profit	$1.75B
SG&A Expenses	$886.00M
Operating Expenses	$1.36B
Operating Income	$392.00M
Interest Expense	$57.00M
Net Income	$555.00M
EPS (Basic)	$0.40
EPS (Diluted)	$0.40
Shares Outstanding (Basic)	1.38B
Shares Outstanding (Diluted)	1.40B

Key Highlights

1Net sales increased by 10.3% to $2.49 billion in Q2 2018 and by 10.2% to $4.87 billion for the first six months of 2018, with strong operational growth.
2Significant growth was observed in the Rhythm and Neuro segment (up 10.8% in Q2) and Cardiovascular segment (up 10.0% in Q2), with Neuromodulation showing exceptional growth of 31.5%.
3The company completed several strategic acquisitions in early 2018, including Cryterion Medical, NxThera, and nVision Medical, indicating a proactive approach to portfolio expansion.
4Reported net income increased significantly to $555 million ($0.40 EPS) in Q2 2018, up from $146 million ($0.11 EPS) in Q2 2017, driven by higher sales and a significant tax benefit related to the settlement of tax disputes and the TCJA.
5Gross profit margin saw a slight decrease to 70.3% in Q2 2018 from 72.0% in Q2 2017, attributed to foreign currency fluctuations, though cost reduction initiatives partially offset this.
6Research and Development (R&D) expenses increased by approximately 13% in Q2 2018 to support product innovation and maintain a healthy pipeline.
7The company ended the period with $208 million in cash and cash equivalents and managed its total debt of $6.49 billion effectively, remaining in compliance with its leverage ratio covenant.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 2018

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions